← FDA DRUG APPROVALS

FDA ANDA · ANDA078165

CARVEDILOL

Sponsor: RUBICON RESEARCH

APPLICATION
ANDA078165
TYPE
ANDA
ORIGINAL APPROVAL
2007-09-05
LATEST ACTION
2020-03-11
ROUTE
ORAL
DOSAGE FORM
TABLET
MARKETING STATUS
Prescription

Products

CARVEDILOLPrescription
CARVEDILOL 25MG · TABLET · ORAL
CARVEDILOLPrescription
CARVEDILOL 6.25MG · TABLET · ORAL
CARVEDILOLPrescription
CARVEDILOL 12.5MG · TABLET · ORAL
CARVEDILOLPrescription
CARVEDILOL 3.125MG · TABLET · ORAL

Approval history

2020-03-11Labeling · Supplement 9 · standardAP
2016-04-26Labeling · Supplement 8 · standardAP
2014-09-25Labeling · Supplement 7 · standardAP
2010-02-16Labeling · Supplement 5AP
2007-10-16Labeling · Supplement 1AP
2007-09-05OriginalLetterAP
VIEW ON DRUGS@FDA ↗

Related on SPEQ

Pharma industryGMP disciplineFDA drug shortagesFDA enforcement & recalls

Source: FDA Drugs@FDA. SPEQ is not affiliated with the FDA; this is a reference view of public FDA data, not medical, legal, or regulatory advice.

Weekly Briefing

Get the Weekly GxP Briefing

Curated regulatory intelligence — enforcement, recalls, guidance, and quality signals — in one practitioner-grade email each week. Free.

Read a past issue →